参考资料:[1] Otsuka and Lundbeck announce FDA acceptance and priority review of sNDA for brexpiprazole for the treatment of agitation associated with Alzheimer's dementia,Retrieved Jan 10th, 2023, from https://www.otsuka.co.jp/en/company/newsreleases/2023/20230110_2.html